Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Palisade Bio (PALI) Income from Continuing Operations (2016 - 2025)

Palisade Bio (PALI) has disclosed Income from Continuing Operations for 16 consecutive years, with 2927000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Income from Continuing Operations rose 18.67% to 2927000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was 11468000.0, a 21.69% increase, with the full-year FY2024 number at 14871000.0, down 13.65% from a year prior.
  • Income from Continuing Operations was 2927000.0 for Q3 2025 at Palisade Bio, down from 2845000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 2311000.0 in Q1 2025 to a low of 4417000.0 in Q3 2022.
  • A 5-year average of 3464630.19 and a median of 3605500.0 in 2023 define the central range for Income from Continuing Operations.
  • Peak YoY movement for Income from Continuing Operations: crashed 84.93% in 2021, then surged 37.1% in 2025.
  • Palisade Bio's Income from Continuing Operations stood at 3661083.0 in 2021, then fell by 5.19% to 3851000.0 in 2022, then increased by 18.0% to 3158000.0 in 2023, then decreased by 7.19% to 3385000.0 in 2024, then increased by 13.53% to 2927000.0 in 2025.
  • Per Business Quant, the three most recent readings for PALI's Income from Continuing Operations are 2927000.0 (Q3 2025), 2845000.0 (Q2 2025), and 2311000.0 (Q1 2025).